Our data suggest that FAF2 may regulate liver PCSK9 levels, potentially through the FOXO3-SIRT6 pathway, thereby contributing to the amelioration of ethanol-induced steatosis and the reduction in circulating LDL cholesterol. The gene discussed is FAF2; the disease is steatosis.